P1206Association between clinical activity and quality of life in patients with Inflammatory Bowel Disease

Abstract Background In inflammatory bowel disease (IBD), therapeutic goals extend beyond clinical, biochemical, and endoscopic remission. The STRIDE-II initiative highlights normalization of health-related quality of life (HRQoL) as a key target. The IBDQ-32, comprising 32 items across intestinal, systemic, emotional, and social domains (scores 32–224), is widely used to assess HRQoL. Higher scores indicate better quality of life. While clinical activity is considered the main predictor of HRQoL, other factors such as comorbidities or treatments may also influence outcomes. This study aimed to evaluate HRQoL in patients with IBD and identify associated factors. Methods Cross-sectional study including adults with confirmed ulcerative colitis (UC) or Crohn’s disease (CD) treated at the Hospital de Especialidades, Centro Médico Nacional La Raza (Mexico), from January to July 2025. All patients completed the IBDQ-32. Clinical activity was assessed with the Truelove-Witts index for UC and the Crohn’s Disease Activity Index for CD. Pearson correlations and multivariable linear regression were used to identify predictors of HRQoL. Results A total of 116 patients were included: 83 (72%) with UC and 33 (28%) with CD; 65% were women. Mean age was 48.4±15.1 years, and disease duration was 7.98±7.4 years. The mean IBDQ-32 score was 138.4±39.4. Domain scores were: intestinal 42.2±12.6, systemic 21.7±7.4, social 45.7±17.9, and emotional 28.7±15.7. global HRQoL showed no correlation with TLW (r = 0.234, p = 0.033) or CDAI (r=-0.190, p = 0.289). The regression model explained 7.6% of HRQoL variability (R²=0.076; p = 0.116). Longer disease duration was the only independent predictor of higher HRQoL (B = 1.14; β = 0.21; p = 0.022). Disease type, gender, and therapies showed no significant associations. Conclusion Clinical activity was not independently associated with HRQoL. Longer disease duration was the only factor linked to better scores, possibly reflecting patient adaptation. These findings underscore the importance of assessing HRQoL comprehensively and not solely based on disease activity indices. References: 1. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD.Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031. 2. Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of quality of life as endpoint for inflammatory bowel disease treatment. Int J Environ Res Public Health. 2021;18(13):7159. doi:10.3390/ijerph18137159. Conflict of interest: Ms. Santoyo Chávez, Martha Alison: No conflict of interest Carrillo Rojas, Javier Ivanovychs: No conflict of interest Varela Martinez, Yessica Nohemí: No conflict of interest del Real Calzada, Carlos Manuel: No conflict of interest Martinez Silva, Francisca: No conflict of interest Mendoza Martinez, Viridiana Montsserrat: No conflict of interest Baños Vazquez, Roberto: No conflict of interest Bueno Hernández, Nallely: No conflict of interest